|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Similar results were obtained when we tested the effects of bcl-xS adenoviral infection on primary normal human mammary epithelial cells and SUM-190 PT cells, (a c-erbB-2 over-expressing human mammary carcinoma cell line) grown on Matrigel.
|
10935511 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
5 human mammary carcinoma cell lines showed both amplification and overexpression of HER-2/neu.
|
1699198 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.
|
7846046 |
1995 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
We conclude that IHC offers a favorable alternative to either Southern analysis or Western immunoblotting in the assessment of c-erbB-2 gene copy number and expression levels of oncoprotein in human mammary carcinoma.
|
1979342 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
|
16091755 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
|
17614302 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation.
|
19617202 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
|
10897039 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
16446318 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
|
12839951 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
11583189 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
12006526 |
2002 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
|
26124351 |
2015 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Molecular profiling of single circulating tumor cells with diagnostic intention.
|
25358515 |
2014 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
|
19436038 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
|
15970926 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
|
16865596 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
|
21638049 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
|
22302033 |
2012 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
|
18086299 |
2007 |